Wave Life Sciences/$WVE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Wave Life Sciences
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
Ticker
$WVE
Sector
Primary listing
Employees
288
Headquarters
Singapore, Singapore
Website
WVE Metrics
BasicAdvanced
$1.1B
-
-$0.84
-1.02
-
Price and volume
Market cap
$1.1B
Beta
-1.02
52-week high
$15.84
52-week low
$5.28
Average daily volume
2.1M
Financial strength
Current ratio
2.558
Quick ratio
2.404
Long term debt to equity
9.226
Total debt to equity
14.755
Profitability
EBITDA (TTM)
-139.916
Gross margin (TTM)
-80.88%
Net profit margin (TTM)
-138.24%
Operating margin (TTM)
-152.76%
Revenue per employee (TTM)
$330,000
Management effectiveness
Return on assets (TTM)
-38.90%
Return on equity (TTM)
-171.41%
Valuation
Price to revenue (TTM)
11.268
Price to book
7.62
Price to tangible book (TTM)
7.62
Price to free cash flow (TTM)
-5.29
Free cash flow yield (TTM)
-18.91%
Free cash flow per share (TTM)
-1.289
Growth
Revenue change (TTM)
-14.98%
Earnings per share change (TTM)
35.40%
3-year revenue growth (CAGR)
32.58%
10-year revenue growth (CAGR)
90.15%
3-year earnings per share growth (CAGR)
-25.68%
10-year earnings per share growth (CAGR)
-6.17%
What the Analysts think about WVE
Analyst ratings (Buy, Hold, Sell) for Wave Life Sciences stock.
Bulls say / Bears say
Wave’s stock jumped 51% after the March 2025 Phase 2 FORWARD-53 trial of WVE-N531 in Duchenne muscular dystrophy delivered a 3.8-second improvement in Time-to-Rise and reversal of muscle fibrosis at 48 weeks.
WVE-006, the GalNAc-RNA editing oligonucleotide for alpha-1 antitrypsin deficiency, completed multidose testing in the 200 mg group and a single dose in the 400 mg group in the RestorAATion-2 trial, highlighting swift clinical progress.
Wave had $208.5 million in cash as of June 30, 2025, giving funding runway into 2027 for its RNA medicines pipeline without a need for immediate new financing.
Wave reported a net loss of $46.9 million in Q1 2025, up from $31.6 million in the previous year, due to much higher R&D and administrative expenses.
Cash and cash equivalents fell from $302.1 million as of December 31, 2024 to $243.1 million at March 31, 2025, showing a high cash burn as clinical activity increased.
Major data releases for WVE-007 in obesity are not expected before the second half of 2025, and the IND submission for WVE-003 in Huntington’s disease is expected only in late 2025, pushing out key potential catalysts.
Data summarised monthly by Lightyear AI. Last updated on 4 Sept 2025.
WVE Financial Performance
Revenues and expenses
WVE Earnings Performance
Company profitability
WVE News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Wave Life Sciences stock?
Wave Life Sciences (WVE) has a market cap of $1.1B as of September 17, 2025.
What is the P/E ratio for Wave Life Sciences stock?
The price to earnings (P/E) ratio for Wave Life Sciences (WVE) stock is 0 as of September 17, 2025.
Does Wave Life Sciences stock pay dividends?
No, Wave Life Sciences (WVE) stock does not pay dividends to its shareholders as of September 17, 2025.
When is the next Wave Life Sciences dividend payment date?
Wave Life Sciences (WVE) stock does not pay dividends to its shareholders.
What is the beta indicator for Wave Life Sciences?
Wave Life Sciences (WVE) has a beta rating of -1.02. This means that it has an inverse relation to market volatility.